GTG Launches Revolutionary geneType Test covering 100% Risk of Breast and Ovarian Cancer
29 mai 2024 08h00 HE
|
Genetic Technologies Ltd
Genetic Technologies Launches Revolutionary geneType Test covering 100% Risk of Breast and Ovarian Cancer
Genenta Welcomes New Directors John L. Cantello, Lauren H. Chung, Armon R. Sharei, and Todd Wider
06 mai 2024 06h25 HE
|
GENENTA SCIENCE SPA
MILAN, Italy and NEW YORK, May 06, 2024 (GLOBE NEWSWIRE) -- Genenta Science (NASDAQ: GNTA), a clinical-stage immuno-oncology company developing a cell-based platform harnessing the power...
GeneType Clinicians’ Adoption Growing - Sales up 5-Fold Year on Year
16 avr. 2024 08h00 HE
|
Genetic Technologies Ltd
GeneType Clinicians’ Adoption Growing - Sales up 5-Fold Year on Year
GTG Global Collaborations and Innovation Update
26 mars 2024 08h00 HE
|
Genetic Technologies Ltd
GTG Global Collaborations and Innovation Update
Laverock Therapeutics announces appointment of Ali Elsley as Finance Director and expansion of team
26 mars 2024 05h00 HE
|
Laverock Therapeutics
STEVENAGE, United Kingdom, March 26, 2024 (GLOBE NEWSWIRE) -- Laverock Therapeutics, a gene-silencing company with a uniquely powerful technology for the development of programmable advanced...
GENE to develop Worlds Most Advanced Comprehensive Risk Test Revolutionising Personalised Healthcare
25 mars 2024 08h00 HE
|
Genetic Technologies Ltd
MELBOURNE, Australia, March 25, 2024 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (NASDAQ:GENE, “Company”, “GENE”), a global leader in guideline-driven genomics-based testing in health, wellness...
GTG to launch U.S. Customer Digital Media Sales Campaign
28 févr. 2024 08h00 HE
|
Genetic Technologies Ltd
MELBOURNE, Australia, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (NASDAQ: GENE, “Company”, “GTG”), is pleased to announce the launch of a wide-reaching customer – targeted...
Launching our most comprehensive test and expanding into new global markets
31 janv. 2024 08h00 HE
|
Genetic Technologies Ltd
MELBOURNE, Australia, Jan. 31, 2024 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (NASDAQ: GENE), is at the forefront in personalised predictive genomics, reshaping the healthcare landscape with...
Genetic Technologies Regains Compliance with Nasdaq Minimum Bid Price Requirement
05 janv. 2024 08h00 HE
|
Genetic Technologies Ltd
MELBOURNE, Australia, Jan. 05, 2024 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (NASDAQ: GENE, “Company”) a global leader in genomics-based tests in health, wellness, and serious disease,...
GeneType's Groundbreaking Saliva Test Transforms Early Disease Detection, Paving the Way for Personalized Wellness
14 déc. 2023 08h00 HE
|
Genetic Technologies Ltd
MELBOURNE, Australia, Dec. 14, 2023 (GLOBE NEWSWIRE) -- Genetic Technologies (GTG) is proud to provide details of a series of recent transformative initiatives. Our commitment to advancing early...